3D Medicines, Inc. ( (HK:1244) ) has provided an update.
3D Medicines, Inc. has announced the composition of its board of directors and their roles within the company. The board consists of executive, non-executive, and independent non-executive directors, with Dr. Gong Zhaolong serving as the executive director. The board has established three committees: Audit, Remuneration, and Nomination, each chaired and populated by various board members. This announcement is significant as it outlines the governance structure of the company, which is crucial for stakeholders to understand the leadership and decision-making processes within 3D Medicines.
More about 3D Medicines, Inc.
3D Medicines, Inc. is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. The company is involved in the development and commercialization of innovative medicines, focusing on advancing healthcare solutions.
YTD Price Performance: 28.25%
Average Trading Volume: 288,092
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.02B
See more data about 1244 stock on TipRanks’ Stock Analysis page.